Bande Manuel F, Santiago María, Mera Purificacion, Piulats Josep María, Blanco María Jose, Rodríguez-Álvarez María Xosé, Capeans Carmela, Piñeiro Antonio, Pardo María
Ocular Oncology Unit Service of Ophthalmology, Complexo Hospitalario Universitario de Santiago, Universidade de Santiago de Compostela, Santiago de Compostela, Spain.
Medical Oncology Department, Catalan Institute of Oncology, Barcelona, Spain.
Invest Ophthalmol Vis Sci. 2015 Nov;56(12):7007-11. doi: 10.1167/iovs.15-17183.
We previously identified the presence of the melanocyte-specific secreted (ME20-S) glycoprotein in secretomes of uveal melanoma (UM) cultures. The aim of this study was to test for the presence and levels of ME20-S in the serum of patients with choroidal nevi and UM and correlate these levels with individual clinical data.
Serum ME20-S levels were determined by ELISA in 111 patients distributed into four categories (53 choroidal nevi, 30 untreated UM, 11 10-year disease-free [DF] UM, 17 hepatic metastatic UM) and 32 age- and sex-matched controls. ME20-S levels were correlated with individual clinical data.
The UM and the metastatic groups showed significantly higher levels of serum ME20-S than the other groups (P < 0.001). ME20-S levels in the DF patients did not differ from those in the control group. In addition, log-transformed serum ME20-S levels showed a positive correlation with the thickness of the lesion mass in UM patients (regression coefficient 0.0689, 95% confidence interval 0.0689-0.1123, R2 = 27.1%).
Elevated ME20-S serum levels are associated with tumor size and advanced stages of UM while low levels are characteristic of DF patients. ME20-S might be a promising serum marker for UM and useful for monitoring metastatic disease.
我们之前在葡萄膜黑色素瘤（UM）培养物的分泌蛋白组中发现了黑色素细胞特异性分泌（ME20-S）糖蛋白。本研究的目的是检测脉络膜痣和UM患者血清中ME20-S的存在情况和水平，并将这些水平与个体临床数据相关联。
采用酶联免疫吸附测定法（ELISA）测定111例患者的血清ME20-S水平，这些患者分为四类（53例脉络膜痣、30例未经治疗的UM、11例无病生存10年的UM、17例肝转移UM）以及32例年龄和性别匹配的对照。ME20-S水平与个体临床数据相关联。
UM组和转移组的血清ME20-S水平显著高于其他组（P < 0.001）。无病生存患者的ME20-S水平与对照组无差异。此外，对数转换后的血清ME20-S水平与UM患者病变肿块的厚度呈正相关（回归系数0.0689，95%置信区间0.0689 - 0.1123，R2 = 27.1%）。
血清ME20-S水平升高与UM的肿瘤大小和晚期阶段相关，而低水平是无病生存患者的特征。ME20-S可能是一种有前景的UM血清标志物，对监测转移性疾病有用。
